EUVIMEDEUVIMED entdecken
ValidierungsstudieOpen Access · CC BY 4.0

First-in-human validation of a DROP-IN β-probe for robotic radioguided surgery: defining optimal signal-to-background discrimination algorithm

Francesco Collamati, Silvio Morganti, Matthias N van Oosterom, Lorenzo Campana, Francesco Ceci, Stefano Luzzago, Carlo Mancini-Terracciano, Riccardo Mirabelli, Gennaro Musi, Francesca Nicolanti, Ilaria Orsi, Fijs W B van Leeuwen und 1 weitere

European Journal of Nuclear Medicine and Molecular Imaging · 2024

DOI: 10.1007/s00259-024-06653-6 ↗

Kurz gefasst

Validierungsstudie in der Zeitschrift European Journal of Nuclear Medicine and Molecular Imaging, 2024. Verfasst von Francesco Collamati und 12 weiteren Autor:innen. Beteiligte Einrichtung: National Institute of Nuclear Physics (INFN), Section of Rome, Rome, Italy. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Surgery, Computer-Assisted, Robotic Surgical Procedures, Algorithms. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: European Commission, Università degli Studi di Roma La Sapienza.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

In radioguided surgery (RGS), radiopharmaceuticals are used to generate preoperative roadmaps (e.g., PET/CT) and to facilitate intraoperative tracing of tracer avid lesions. Within RGS, there is a push toward the use of receptor-targeted radiopharmaceuticals, a trend that also has to align with the surgical move toward minimal invasive robotic surgery. Building on our initial ex vivo evaluation, this study investigates the clinical translation of a DROP-IN β probe in robotic PSMA-guided prostate cancer surgery.

Methods

A clinical-grade DROP-IN β probe was developed to support the detection of PET radioisotopes (e.g., 68 Ga). The prototype was evaluated in 7 primary prostate cancer patients, having at least 1 lymph node metastases visible on PSMA-PET. Patients were scheduled for radical prostatectomy combined with extended pelvic lymph node dissection. At the beginning of surgery, patients were injected with 1.1 MBq/kg of [ 68 Ga]Ga-PSMA. The β probe was used to trace PSMA-expressing lymph nodes in vivo. To support intraoperative decision-making, a statistical software algorithm was defined and optimized on this dataset to help the surgeon discriminate between probe signals coming from tumors and healthy tissue.

Results

The DROP-IN β probe helped provide the surgeon with autonomous and highly maneuverable tracer detection. A total of 66 samples (i.e., lymph node specimens) were analyzed in vivo, of which 31 (47%) were found to be malignant. After optimization of the signal cutoff algorithm, we found a probe detection rate of 78% of the PSMA-PET-positive samples, a sensitivity of 76%, and a specificity of 93%, as compared to pathologic evaluation.

Conclusion

This study shows the first-in-human use of a DROP-IN β probe, supporting the integration of β radio guidance and robotic surgery. The achieved competitive sensitivity and specificity help open the world of robotic RGS to a whole new range of radiopharmaceuticals.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Prostatic NeoplasmsSurgery, Computer-AssistedRobotic Surgical ProceduresAlgorithmsHumansMalePositron Emission Tomography Computed TomographyAgedRadiopharmaceuticalsGallium RadioisotopesBeta ParticlesMiddle AgedGlutamate Carboxypeptidase IIGallium IsotopesProstatectomyLymphatic Metastasis

Stichwörter der Autor:innen

Image-guided surgeryMolecular imagingPETProstate cancerRobotic surgeryβ radioguided surgery

Substanzen

gallium 68 PSMA-11RadiopharmaceuticalsGallium RadioisotopesGlutamate Carboxypeptidase IIGallium Isotopes

Autor:innen und Institutionen

  • National Institute of Nuclear Physics (INFN), Section of Rome, Rome, Italy.
  • Interventional Molecular Imaging Laboratory, Department of Radiology, Leiden University Medical Center, Leiden, The Netherlands.
  • Department of Scienze di Base e Applicate per l'Ingegneria (SBAI), Sapienza University of Rome, Rome, Italy.
  • Division of Nuclear Medicine, IEO, European Institute of Oncology IRCCS, Milan, Italy.
  • Department of Oncology and Hematology-Oncology, University of Milan, Milan, Italy.
  • Department of Urology, IEO European Institute of Oncology, IRCCS, Milan, Italy.

Förderung

  • European Commission
  • Università degli Studi di Roma La Sapienza

Zitieren

APA

Collamati, F., Morganti, S., van Oosterom, M. N., Campana, L., Ceci, F., Luzzago, S., Mancini-Terracciano, C., Mirabelli, R., Musi, G., Nicolanti, F., Orsi, I., van Leeuwen, F. W. B., & Faccini, R. (2024). First-in-human validation of a DROP-IN β-probe for robotic radioguided surgery: defining optimal signal-to-background discrimination algorithm. European Journal of Nuclear Medicine and Molecular Imaging. https://doi.org/10.1007/s00259-024-06653-6

Vancouver

Collamati F, Morganti S, van Oosterom MN, Campana L, Ceci F, Luzzago S, et al. First-in-human validation of a DROP-IN β-probe for robotic radioguided surgery: defining optimal signal-to-background discrimination algorithm. European Journal of Nuclear Medicine and Molecular Imaging. 2024. doi:10.1007/s00259-024-06653-6

BibTeX
@article{Collamati2024,
  author = {Collamati, Francesco and Morganti, Silvio and van Oosterom, Matthias N and Campana, Lorenzo and Ceci, Francesco and Luzzago, Stefano and Mancini-Terracciano, Carlo and Mirabelli, Riccardo and Musi, Gennaro and Nicolanti, Francesca and Orsi, Ilaria and van Leeuwen, Fijs W B and Faccini, Riccardo},
  title = {First-in-human validation of a DROP-IN β-probe for robotic radioguided surgery: defining optimal signal-to-background discrimination algorithm},
  journal = {European Journal of Nuclear Medicine and Molecular Imaging},
  year = {2024},
  doi = {10.1007/s00259-024-06653-6}
}
Kostenlos starten →